COMMERCIAL PARTNERSHIPS
OUR PARTNERS are leading biotechnology firms with highly innovative specialty products and ambitions to extend their global patient reach.
WE ARE their one-stop shop for commercial success in emerging markets. Through our strategic approach, we increase the value of our partnered products by extending and broadening their commercial life cycle, ensuring better access to patients as well as greater market penetration and reach
Utilizing a phased approach tailored to emerging markets, we optimize regulatory and reimbursement pathways to unlock the full potential of products in line with our biopharma partner’s strategy.
We ensure the success of high-end innovative medicines by leveraging our geographic footprint and in-house expertise in medicine, access, policy development, reimbursement and commercialization.
We are a flexible, pragmatic, patient-focused and dynamic partner committed to expanding access to life-saving medicines.
Together with our partners, we make a holistic assessment and propose an approach that meets the strategic objectives of our partners in every single market.
Our scalable, full-service organizational structure is adapted to the local environment and supported by centralized governance. Our winning capabilities and expertise are grouped into the following areas:
- Medical Affairs
- Market Access
- Commercial Operations
- Regulatory, PV & Compliance
- Finance & Administration
OUR 13 international locations deliver our commercial capabilities across key emerging markets in four regions:
- Latin America
- APAC
- MENA, Türkiye, India
- Russia and CIS
WE ENGAGE directly, country by country, with key opinion leaders (KOLs), healthcare professionals (HCPs) and institutions (HCIs), treatment centres of excellence, patient advocacy organisations (PAOs), public and private payors, charities and regulatory agencies.
Examples of programmes executed across various geographical regions are listed below:
| Therapeutic Area | Indication | Geographical Scope |
|---|---|---|
| Oncology | ESR1 Mutated Breast Cancer | Emerging Markets |
| Andrenocortical Carcinoma (ACC) | Regional/Cluster | |
| Wilm's Tumor | Regional/Cluster | |
| Haemato-oncology | High Risk Neuroblastoma (HRNB) | Emerging Markets |
| Acute Lymphoblastic Leukemia (ALL) | Emerging Markets | |
| Metabolic Disease Orphan | Alagille Syndrome (ALGS) | Regional/Cluster |
| Congenital or Acquired Generalized Lipodystrophy (GL) | Regional/Cluster | |
| Homozygous Familial Hypercholesterolemia | Regional/Cluster | |
| Progressive Familial Intrahepatic Cholestasis (PFIC) | Regional/Cluster | |
| Neurology Orphan | Allan Herndon Dudley Syndrome (MCT8 Defficiency) | Regional/Cluster |
| Duchenne Muscular Dystrophy | Regional/Cluster | |
| Immunology Orphan | Multicentric Castelman Disease | Emerging Markets |
| Dermatology Orphan | Epidermolysis Bullosa (EB) | Regional/Cluster |
| Ophthalmology Orphan | Neurotrophic Keratitis | Emerging Markets |
| Ophthalmology orphan | Neurotrophic keratitis | Targeted markets |
| Dermatology orphan | Epidermolysis bullosa (EB) | Targeted markets |
